Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review

Journal of Clinical Psychiatry

Volumn 70, Issue 7, 2009, Pages 1041-1050

  Simon, Viktoria ^a   Van Winkel, Ruud ^b,c   De Hert, Marc ^c  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; FLUVOXAMINE; GLUCOSE; HALOPERIDOL; INSULIN; LIPID; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SERTINDOLE; TRIACYLGLYCEROL; ZIPRASIDONE;

ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; LOW DRUG DOSE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHILD; CLOZAPINE; CONTROLLED CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOXICITY; FEMALE; HUMANS; INSULIN; MALE; METABOLIC SYNDROME X; RISPERIDONE; TREATMENT OUTCOME; TRIGLYCERIDES; WEIGHT GAIN;

EID: 65749092920     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08r04392     Document Type: Article

References (83)

1. Arato M, O'Connor R, Meltzer HY. A 1-year, double-blind, placebo-controlled trial of ziprasidone 40, 80 and 160 mg/day in chronic schizophrenia: the Ziprasidone Extended Use in Schizophrenia (ZEUS) study. Int Clin Psychopharmacol. 2002;17(5):207-215.
2. Arvanitis LA, Miller BG and the The Seroquel Trial 13 Study Group. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42(4):233-246.
3. Fitton A, Heel RC. Clozapine: a review of its pharmacological properties, and therapeutic use in schizophrenia. Drugs. 1990;40(5):722-747.
4. Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs. 1997;53(2):281-298.
5. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res. 2003;61(2-3):123-136.
6. Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol. 2004;19(2):63-69.
7. Perquin L, Steinert T. A review of the efficacy, tolerability and safety of sertindole in clinical trials. CNS Drugs. 2004;18(suppl 2):19-30.
8. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686- 1696.
9. Fleischhacker WW, Cetkovich-Bakmas M, De Hert M, et al. Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry. 2008;69(4):514-519.
10. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol. 2005;19(6 suppl):16-27.
11. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
12. Citrome L. The effectiveness criterion: balancing efficacy against the risks of weight gain. J Clin Psychiatry. 2007;68(suppl 12):12-17.
13. American Diabetes Association (ADA), American Psychiatric Association (APA), American Association of Clinical Endocrinology (AACE), North American Association for the Study of Diabetes. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
14. De Hert M, van Eyck D, De Nayer A. Metabolic abnormalities associated with second-generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol. 2006;21(suppl 2):S11-S15.
15. De Nayer A, De Hert M, Scheen A, et al. Belgian consensus on metabolic problems associated with atypical antipsychotics [conference report]. Int J Psych Clin Pract. 2005;9(2):130-137
16. Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf. 2006;29(4):303-319.
17. Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatry. 2006;51(8):480-491.
18. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(suppl 4):8-13.
19. Russell JM, Mackell JA. Bodyweight gain associated with atypical antipsychotics: epidemiology and therapeutic implications. CNS Drugs. 2001;15(7):537-551.
20. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry. 2008;13(1):27-35.
21. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology. 2003;28(3):519-526.
22. Matsui-Sakata A, Ohtani H, Sawada Y. Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus. Drug Metab Pharmacokinet 2005;(5):366-378
23. 1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci USA. 2007;104(9):3456-3459.
24. Haddad PM, Sharma SG. Adverse effects of atypical antipsychotics: differential risk and clinical implications. CNS Drugs. 2007;21(11):911-936.
25. Lindstrom E, Levander S. Sertindole: efficacy and safety in schizophrenia. Expert Opin Pharmacother. 2006;7(13):1825-1834.
26. Murdoch D, Keating GM. Sertindole: A review of its use in schizophrenia. CNS Drugs. 2006;20(3):233-255.
27. 3 receptor binding-affinity could predict the risk of antipsychotics to induce type 2 diabetes. Methods Find Exp Clin Pharmacol. 2005;27(5):289-304.
28. Wirshing DA, Spellberg BJ, Erhart SM, et al. Novel antipsychotics and new-onset diabetes. Biol Psychiatry. 1998;44(8):778-783.
29. Gilles M, Wilke A, Kopf D, et al. Antagonism of the serotonin (5-HT)-2 receptor and insulin sensitivity: implications for atypical antipsychotics. Psychosom Med. 2005;67(5):748-751.
30. 2C receptor gene. Nat Med. 1998;4(10):1152-1156.
31. Ader M, Kim SP, Catalano KJ, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes. 2005;54(3):862-871.
32. 2C receptor gene polymorphism. Lancet. 2002;359(9323):2086-2087.
33. 2C receptor and leptin genes are associated with antipsychotic drug-induced weight gain in Caucasian subjects with a first-episode psychosis. Pharmacogenet Genomics. 2005;15(4):195-200.
34. de Leon J, Diaz FJ, Josiassen RC, et al. Weight gain during a double-blind multidosage clozapine study. J Clin Psychopharmacol. 2007;27(1):22-27.
35. Frankenburg FR, Zanarini MC, Kando J, et al. Clozapine and body mass change. Biol Psychiatry. 1998;43(7):520-524.
36. Lu M-L, Lane H-Y, Lin S-K, et al. Adjunctive fluvoxamine inhibits clozapine-related weight gain and metabolic disturbances. J Clin Psychiatry. 2004;65(6):766-771.
37. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry. 2005;66(9):1116-1121.
38. Hummer M, Kemmler G, Kurz M, et al. Weight gain induced by clozapine. Eur Neuropsychopharmacol. 1995;5(4)437-440.
39. Jalenques I, Tauveron I, Albuissian E., et al. Weight gain and clozapine [in French]. Encephale. 1996;22(Spec No 3):77-79
40. Melkersson KI, Hulting AL, Brismar KE. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses. J Clin Psychiatry. 1999;60(11):783-791.
41. Melkersson KI, Dahl ML. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses. Psychopharmacology (Berl). 2003;170(2):157-166.
42. Melkersson KI, Scordo MG, Gunes A, et al. Impact of CYP1A2 and CYP2D6 polymorphisms on drug metabolism and on insulin and lipid elevations and insulin resistance in clozapine-treated patients. J Clin Psychiatry. 2007;68(5):697-704.
43. Buur-Rasmussen B, Brosen K. Cytochrome P450 and therapeutic drug monitoring with respect to clozapine. Eur Neuropsychopharmacol. 1999;9(6):453-459.
44. Dunayevich E, Sethuraman G, Wei H, et al. Olanzapine dose and weight gain. Presented at the 8th World Congress of Biological Psychiatry; Jun 28-Jul 3, 2005; Vienna, Austria.
45. Hennen J, Perlis RH, Sachs G, et al. Weight gain during treatment of bipolar I patients with olanzapine. J Clin Psychiatry. 2004;65(12):1679-1687.
46. Jones B, Basson BR, Walker DJ, et al. Weight change and atypical antipsychotic treatment in patients with schizophrenia. J Clin Psychiatry. 2001;62(suppl 2):41-44.
47. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry. 2001;62(2):92-100.
48. Lee E, Leung C-M, Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. J Clin Psychiatry. 2004;65(6):864-866.
49. Beasley CM Jr, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7(2):125-137.
50. Kinon BJ, Volavka J, Stauffer V, et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder. A randomized, double-blind, fixed-dose study. J Clin Psychopharmacol. 2008;28(4):392-400.
51. Kinon BJ, Volavka J, Bergstorm J, et al. Steady state concentrations after standard and higher dose of oral olanzapine in acutely ill patients with schizophrenia or schizoaffective disorder with suboptimal prior response. Neuropsychopharmacology. 2006;31:S115.
52. Lindenmayer J-P, Czobor P, Volavka J, et al. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. J Clin Psychiatry. 2002;63(10):931-935.
53. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25(3):250-254.
54. Mitchell M, Riesenberg R, Bari MA, et al. A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects. Clin Ther. 2006;28(6):881-892.
55. Sahoo S, Mishra B, Akhtar S. Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report. Br J Clin Pharmacol. 2007;64(5):715-716.
56. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825-835.
57. Peuskens J, on behalf of the Risperidone Study Group. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166(6):712-726.
58. Lane H-Y, Chang Y-C, Cheng Y-C, et al. Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia. J Clin Psychiatry. 2003;64(3):316-320.
59. Buitelaar JK. Open-label treatment with risperidone of 26 psychiatrically hospitalized children and adolescents with mixed diagnoses and aggressive behavior. J Child Adolesc Psychopharmacol. 2000;10(1):19-26.
60. Hellings JA, Zarcone JR, Crandall K, et al. Weight gain in a controlled study of risperidone in children, adolescents, and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001;11(3)229-238.
61. Kelly DL, Conley RR, Love RC, et al. Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. J Child Adolesc Psychopharmacol. 1998;8(3):151-159.
62. Cohen S, Glazewski R, Khan S, et al. Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. J Clin Psychiatry. 2001;62(2):114-116.
63. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med. 2002;346(1):16-22.
64. Fleischhacker WW, Eerdekens M, Karcher K, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry. 2003;64(10):1250-1257.
65. Brecher M, Rak IW, Melvin K, et al. The long-term effect of quetiapine (Seroquel) monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract. 2000;4(4):287-291.
66. Jones A, Rak IW, Raniwalla J. Weight changes in patients treated with quetiapine. Poster presented at the 153rd Annual Meeting of the American Psychiatric Association; May 13-18, 2000; Chicago, Ill.
67. Rak IW, Jones AM, Raniwalla J, et al. Weight changes in patients treated with Seroquel (quetiapine) [abstract]. Schizophr Res. 2000;41(1):206.
68. Brecher M, Leong RW, Stening G, et al. Quetiapine and long-term weight change: a comprehensive data review of patients with schizophrenia. J Clin Psychiatry. 2007;68(4):597-603.
69. Small JG, Hirsch SR, Arvanitis LA, et al, and the Seroquel Study Group. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry. 1997;54(6):549-557.
70. Kinon BJ, Ahl J, Stauffer VL, et al. Dose response and atypical antipsychotics in schizophrenia. CNS Drugs. 2004;18(9):597-616.
71. Daniel DG, Zimbroff DL, Potkin SG, et al, and the Ziprasidone Study Group. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial.Neuropsychopharmacology. 1999;20(5):491-505.
72. Keck P Jr, Buffenstein A, Ferguson J, et al. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology (Berl). 1998;140(2):173-184.
73. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry. 2003;60(7):681-690.
74. Tschoner A, Engl J, Laimer M, et al. Metabolic side effects of antipsychotic medication. Int J Clin Pract. 2007;61(8):1356-1370.
75. Leucht S, Wagenpfeil S, Hamann J, et al. Amisulpride is an "atypical" antipsychotic associated with low weight gain. Psychopharmacology (Berl). 2004;173(1-2):112-115.
76. Kasper S. Sertindole: safety and tolerability profile. Int J Psych Clin Pract. 2002;6(suppl 1):S27-S32.
77. Hale A, van der Burght M, Friberg HH, et al. Dose ranging study comparing 4 doses of sertindole and 1 dose of haloperidol in schizophrenic patients [abstract]. Eur Neuropsychopharmacol. 1996;6(suppl 1):61.
78. van Kammen DP, McEvoy JP, Targum SD, et al. A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia. Psychopharmacology (Berl). 1996;124(1-2):168-175.
79. Zborowski J, Schmitz P, Staser J, et al. Efficacy and safety of sertindole in a trial of schizophrenic patients. Poster presented at the 15th Annual Convention of Scientific Programs, Biological Psychiatry, Society of Biological Psychiatry; May 20, 1995; Miami, Fla.
80. Zimbroff DL, Kane JM, Tamminga CA, et al, and the Sertindole Study Group. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry. 1997;154(6):782-791.
81. Hale AS. A review of the safety and tolerability of sertindole. Int Clin Psychopharmacol. 1998;13(suppl 3):S65-S70.
82. Wetterling T. Bodyweight gain with atypical antipsychotics: a com parative review. Drug Saf. 2001;24(1):59-73.
83. Elman I, Borsook D, Lucas SE. Food intake and reward mechanisms in patients with schizophrenia: implications for metabolic disturbances and treatment with second-generation antipsychotic agents. Neuropsychopharmacology. 2006;31(10):2091-2120.